BACKGROUND: The objective of this study was to independently evaluate the objective response rate of sorafenib and sorafenib plus low-dose interferon-alfa 2b (IFN) as frontline therapy in patients with metastatic renal cell carcinoma (mRCC). METHODS:Untreated patients with clear cell mRCC were randomized to receive sorafenib 400 mg orally twice daily or sorafenib 400 mg orally twice daily plus subcutaneous IFN 0.5 million U (MU) twice daily. Primary endpoints included the objective response rate (ORR) and safety. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Exploratory endpoints included the predictive value of tumor tissue biomarkers. RESULTS:Eighty patients were enrolled. The median follow-up was 19.7 months (range, 0-34.2 months). The ORR was 30% (95% confidence interval [CI], 16.6%-46.5%) in the sorafenib arm and 25% (95% CI, 12.7%-41.2%) in the combination arm. The median PFS was 7.39 months in the sorafenib-alone arm (95% CI, 5.52-9.20 months) and 7.56 months in the sorafenib plus IFN arm (95% CI, 5.19-11.07 months). The median OS was 27.04 months in the combination arm (95% CI, from 22.31 to not attained) and was not reached in the sorafenib arm. Toxicities were comparable in both arms. In a multivariate model, increased phosphorylated protein kinase B (pAKT) levels were associated with poorer PFS (hazard ratio, 1.04; 95% CI, 1.00-1.08; P = .0411) and OS (hazard ratio, 1.15; 95% CI, 1.02-1.29; P = .0173). CONCLUSIONS: The addition of low-dose IFN to sorafenib resulted in efficacy outcomes that were comparable to those achieved with sorafenib monotherapy. The current results indicated that pAKT levels may predict for clinical outcome, but further mechanistic study is required. Copyright 2010 American Cancer Society.
RCT Entities:
BACKGROUND: The objective of this study was to independently evaluate the objective response rate of sorafenib and sorafenib plus low-dose interferon-alfa 2b (IFN) as frontline therapy in patients with metastatic renal cell carcinoma (mRCC). METHODS: Untreated patients with clear cell mRCC were randomized to receive sorafenib 400 mg orally twice daily or sorafenib 400 mg orally twice daily plus subcutaneous IFN 0.5 million U (MU) twice daily. Primary endpoints included the objective response rate (ORR) and safety. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Exploratory endpoints included the predictive value of tumor tissue biomarkers. RESULTS: Eighty patients were enrolled. The median follow-up was 19.7 months (range, 0-34.2 months). The ORR was 30% (95% confidence interval [CI], 16.6%-46.5%) in the sorafenib arm and 25% (95% CI, 12.7%-41.2%) in the combination arm. The median PFS was 7.39 months in the sorafenib-alone arm (95% CI, 5.52-9.20 months) and 7.56 months in the sorafenib plus IFN arm (95% CI, 5.19-11.07 months). The median OS was 27.04 months in the combination arm (95% CI, from 22.31 to not attained) and was not reached in the sorafenib arm. Toxicities were comparable in both arms. In a multivariate model, increased phosphorylated protein kinase B (pAKT) levels were associated with poorer PFS (hazard ratio, 1.04; 95% CI, 1.00-1.08; P = .0411) and OS (hazard ratio, 1.15; 95% CI, 1.02-1.29; P = .0173). CONCLUSIONS: The addition of low-dose IFN to sorafenib resulted in efficacy outcomes that were comparable to those achieved with sorafenib monotherapy. The current results indicated that pAKT levels may predict for clinical outcome, but further mechanistic study is required. Copyright 2010 American Cancer Society.
Authors: John D Hainsworth; Jeffrey A Sosman; David R Spigel; Donna L Edwards; Cara Baughman; Anthony Greco Journal: J Clin Oncol Date: 2005-10-03 Impact factor: 44.544
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Zofia von Marschall; Arne Scholz; Thorsten Cramer; Georgia Schäfer; Michael Schirner; Kjell Oberg; Bertram Wiedenmann; Michael Höcker; Stefan Rosewicz Journal: J Natl Cancer Inst Date: 2003-03-19 Impact factor: 13.506
Authors: Christopher W Ryan; Bryan H Goldman; Primo N Lara; Philip C Mack; Tomasz M Beer; Catherine M Tangen; Dianne Lemmon; Chong-Xian Pan; Harry A Drabkin; E David Crawford Journal: J Clin Oncol Date: 2007-08-01 Impact factor: 44.544
Authors: Madeleine M Hipp; Norbert Hilf; Steffen Walter; Daniela Werth; Katharina M Brauer; Markus P Radsak; Toni Weinschenk; Harpreet Singh-Jasuja; Peter Brossart Journal: Blood Date: 2008-02-29 Impact factor: 22.113
Authors: James B Brugarolas; Francisca Vazquez; Archana Reddy; William R Sellers; William G Kaelin Journal: Cancer Cell Date: 2003-08 Impact factor: 31.743
Authors: E Jonasch; E Hasanov; P G Corn; T Moss; K R Shaw; S Stovall; V Marcott; B Gan; S Bird; X Wang; K A Do; P F Altamirano; A J Zurita; L A Doyle; P N Lara; N M Tannir Journal: Ann Oncol Date: 2017-04-01 Impact factor: 32.976
Authors: Federico A Monzon; Karla Alvarez; Lief Peterson; Luan Truong; Robert J Amato; Joan Hernandez-McClain; Nizar Tannir; Anil V Parwani; Eric Jonasch Journal: Mod Pathol Date: 2011-07-01 Impact factor: 7.842
Authors: K Hellbach; A Sterzik; W Sommer; M Karpitschka; N Hummel; J Casuscelli; M Ingrisch; M Schlemmer; A Graser; Michael Staehler Journal: Eur Radiol Date: 2016-09-27 Impact factor: 5.315
Authors: Yangsook Song Green; Timothy Sargis; Ethan Conrad Reichert; Eleanor Rudasi; Daniel Fuja; Eric Jonasch; Mei Yee Koh Journal: Mol Cancer Res Date: 2019-01-31 Impact factor: 5.852
Authors: Belal Al-Husein; Maha Abdalla; Morgan Trepte; David L Deremer; Payaningal R Somanath Journal: Pharmacotherapy Date: 2012-12 Impact factor: 4.705